

Sadhak Sengupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5235635/publications.pdf>

Version: 2024-02-01

21
papers

981
citations

623734

14
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

1708
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 821-833.	7.0	21
2	IMMU-39. FIRST-IN-KIND T CELLS CARRYING A CHIMERIC ANTIGEN RECEPTOR AGAINST AN EXTRACELLULAR MATRIX PROTEIN TARGET GLIOBLASTOMA CELLS AND SHOW ANTI-TUMOR EFFICACY. <i>Neuro-Oncology</i> , 2018, 20, vi129-vi130.	1.2	0
3	EXTH-44. TARGETING GLIOMA STEM CELLS WITH CAR-T IMMUNOTHERAPY IN XENOGRFT ANIMAL MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi94-vi94.	1.2	0
4	Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. <i>Cancer Letters</i> , 2018, 433, 131-139.	7.2	37
5	Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy. <i>Rhode Island Medical Journal</i> (2013), 2017, 100, 39-42.	0.2	0
6	IMST-05. NOVEL CAR-T CELLS TARGETING THE EXTRACELLULAR MATRIX OF GLIOBLASTOMA INDUCE STRONG ANTI-TUMOR IMMUNE RESPONSE. <i>Neuro-Oncology</i> , 2016, 18, vi86-vi87.	1.2	0
7	Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	40
8	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. <i>Neuro-Oncology</i> , 2014, 16, 1304-1312.	1.2	131
9	Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	100
10	Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells. <i>Clinical Cancer Research</i> , 2012, 18, 5949-5960.	7.0	124
11	Mechanisms of Immune Evasion by Gliomas. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 53-76.	1.6	93
12	Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. <i>Neuro-Oncology</i> , 2011, 13, 1308-1323.	1.2	106
13	Enhanced Transduction and Replication of RGD-Fiber Modified Adenovirus in Primary T Cells. <i>PLoS ONE</i> , 2011, 6, e18091.	2.5	10
14	Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma. <i>PLoS ONE</i> , 2010, 5, e9750.	2.5	67
15	The Presence of IL-17A and T Helper 17 Cells in Experimental Mouse Brain Tumors and Human Glioma. <i>PLoS ONE</i> , 2010, 5, e15390.	2.5	51
16	Bone Marrow Mesenchymal Stem Cells Loaded With an Oncolytic Adenovirus Suppress the Anti-adenoviral Immune Response in the Cotton Rat Model. <i>Molecular Therapy</i> , 2010, 18, 1846-1856.	8.2	70
17	Short Hairpin RNA-Mediated Fibronectin Knockdown Delays Tumor Growth in a Mouse Glioma Model. <i>Neoplasia</i> , 2010, 12, 837-847.	5.3	50
18	Challenges in Clinical Design of Immunotherapy Trials for Malignant Glioma. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 201-214.	1.7	39

#	ARTICLE	IF	CITATIONS
19	Adjuvant Induced Glucose Uptake by Activated T Cells is not Correlated with Increased Survival. <i>Advances in Experimental Medicine and Biology</i> , 2008, 614, 65-72.	1.6	5
20	Unrestrained Glycogen Synthase Kinase-3 β Activity Leads to Activated T Cell Death and Can Be Inhibited by Natural Adjuvant. <i>Journal of Immunology</i> , 2007, 178, 6083-6091.	0.8	24
21	Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose. <i>Immunobiology</i> , 2005, 210, 647-659.	1.9	13